Clinical Trial VICCHEM1284


Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Principal Investigator(s)

John Greer


  • Protocol No. VICCHEM1284
  • Open Date: 06/05/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
  • Disease Sites: Lymphoma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01728805
  • Secondary Protocol No: 0761-010



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.